Form of Underwriter’s Warrant Agreement]Underwriter’s Warrant Agreement • September 15th, 2017 • Genprex, Inc. • Pharmaceutical preparations • Texas
Contract Type FiledSeptember 15th, 2017 Company Industry JurisdictionTHIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [ ] [DATE THAT IS SIX MONTHS FROM THE CLOSING DATE OF THE OFFERING]. VOID AFTER 5:00 P.M., EASTERN TIME, [ ] [DATE THAT IS FIVE YEARS FROM THE CLOSING DATE OF THE OFFERING].
GENPREX, INC. SUBSCRIPTION AGREEMENTSubscription Agreement • September 15th, 2017 • Genprex, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 15th, 2017 Company Industry JurisdictionThis Subscription Agreement (this “Subscription Agreement”) is dated , 2017, by and between the undersigned identified on the Signature Page hereto (the “Investor”) and Genprex, Inc., a Delaware corporation (the “Company”).
AMENDMENT NO. 1 TO CLINICAL STUDY AGREEMENTClinical Study Agreement • September 15th, 2017 • Genprex, Inc. • Pharmaceutical preparations
Contract Type FiledSeptember 15th, 2017 Company IndustryThis Amendment No. 1 (this “Amendment”) is made and entered into this 25th, day of June, 2015 (“Effective Date”), by and between The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 (“M.D. Anderson”), a member institution of The University of Texas System (“System”), and Genprex, Inc. (“Sponsor”).
CLINICAL STUDY AGREEMENTClinical Study Agreement • September 15th, 2017 • Genprex, Inc. • Pharmaceutical preparations • Texas
Contract Type FiledSeptember 15th, 2017 Company Industry JurisdictionTHIS Agreement is made and entered into this 10th day of February, 2014 (“Effective Date”), by and between The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 (“MD Anderson”), a member institution of The University of Texas System (“System”), and Genprex, Inc., (“Sponsor”), for purposes of confirming the parties intent and agreement to conduct a clinical study and evaluation as set forth herein. Accordingly, MD Anderson and Sponsor agree as follows: